NRAS Gain

CI-VAR-00417095Explore in graph →CIViC 5583

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
NRAS Gain	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID13293 In a retrospective cohort of 657 patients with melanoma, 92 (14.0%) had NRAS copy-number gain (>2 copies). Patients with NRAS gain had shorter median overall survival than patients with normal NRAS co… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC	civic
NRAS Gain	Binimetinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID6899 In melanoma preclinical models, increased NRAS expression enhanced sensitivity to binimetinib in NRAS-copy-normal A875 cells, whereas NRAS knockdown decreased binimetinib sensitivity in NRAS-gain WM26… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.